Abstract:Background . Previous studies have demonstrated that the tumor-stromal ratio (TSR) was an independent prognostic factor in several types of carcinomas. This study aimed at exploring the prognostic significance of the TSR in invasive breast cancer using immunohistochemistry (IHC)-stained tissue microarrays (TMAs) and integrating the TSR into the traditional tumor-node-metastasis (TNM) staging system. Methods . The prepared 7 TMAs containing 240 patients with 480 invasive BC specimens were stained with cytokeratin (CK) by the IHC staining method. The ratio of tumor cells and stromal cells was visually assessed. TSR > 1 and TSR ≤ 1 were categorized as the high TSR (low stroma) and low TSR (high stroma) groups, respectively, and the prognostic value of the TSR at 5-year disease-free survival (5-DFS) was analyzed. A new Ts-TNM (tumor stroma-tumor-node-metastasis) staging system was established and assessed. Results . IHC staining of CK could specifically label tumor cells with clear contrast, making it easy to manually assess TSR. High TSR (low stroma) and low TSR (high stroma) were observed in 52.5% ( n = 126) and 47.5 ( n = 114) of the cases, according to the division of value 1. A Kaplan–Meier analysis showed that patients in the low TSR group had a worse 5-DFS compared with patients in the high TSR group ( P = 0.022 ). Multivariable analysis indicated that the T stage ( P = 0.014 ), N status ( P < 0.001 ), histological grade ( P < 0.001 ), estrogen receptor status ( P = 0.015 ), and TSR ( P = 0.011 ) were independent prognostic factors of invasive BC patients. The new Ts-TNM staging system combining TSR, tumor staging, lymph node status, and metastasis staging was established. The receiver operating characteristic (ROC) curve analysis demonstrated that the ability of the Ts-TNM staging system to predict recurrence was not lower than that of the TNM staging system. Conclusions . This study confirms that the TSR is a prognostic indicator for invasive breast cancer. The Ts-TNM staging system containing stromal and tumor information may optimize risk stratification for invasive breast cancer.

Tumor-stroma Ratio is a Prognostic Factor for Survival in Hepatocellular Carcinoma Patients after Liver Resection or Transplantation.

Tumor-stroma Ratio (TSR) in Non-Small Cell Lung Cancer (NSCLC) Patients after Lung Resection is a Prognostic Factor for Survival.

Tumor-stroma Ratio is an Independent Predictor for Survival in NSCLC.

Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer]

Effect of tumor-stroma ratio in prognosis evaluation of tumor

Prognostic Significance of the Tumor-Stroma Ratio in Gallbladder Cancer.

Tumor-Stroma Ratio is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma

Tumor–stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma

Value of tumor stroma ratio in evaluating the prognosis of patients with stage Ⅱ and Ⅲ colorectal cancer

Prognostic values of tumor-stroma ratio and tumor-infiltrating lymphocytes in stagesⅡandⅢcolorectal cancer

Prognostic Significance of Tumor–Stroma Ratio (TSR) in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis

Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies

Prognostic Value of Tumor-stroma Ratio in Oral Squamous Cell Carcinoma: Contribution of Cancer Associated Fibroblasts

The prognostic value of tumor-stromal ratio combined with TNM staging system in esophagus squamous cell carcinoma

Prognostic Significance of the Tumor-Stromal Ratio in Invasive Breast Cancer and a Proposal of a New Ts-TNM Staging System

Prognostic value of the tumor-stroma ratio in patients with T 1 high-grade bladder cancer undergoing transurethral resection of bladder tumor

Preoperative C-reactive Protein/albumin Ratio to Predict Mortality and Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection.

Predictive value of tissue TSR for the efficacy of immunotherapy in non-small lung cancer

The Tumour-Associated Stroma Correlates with Poor Clinical Outcomes and Immunoevasive Contexture in Patients with Upper Tract Urothelial Carcinoma: Results from a Multicenter Real-World Study (TSU-01 Study).

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer

Combining the Tumor-Stroma Ratio with Tumor-Infiltrating Lymphocytes Improves the Prediction of Pathological Complete Response in Breast Cancer Patients.